search for




 

Safety and efficacy of peripheral nutrition fluid (MG-TNA®) in patients undergoing surgery for hepatobiliary and pancreatic disease: Results of a phase 4 trial
Ann Hepatobiliary Pancreat Surg 2019 May;23(2):133-7
Published online May 31, 2019;  https://doi.org/10.14701/ahbps.2019.23.2.133
Copyright © 2019 Korean Association of Hepato-Biliary-Pancreatic Surgery.

Young-Dong Yu1, Jae-hyun Han2, Sung-Won Jung3, Dong-Sik Kim1

1Division of HBP Surgery & Liver Transplantation, Department of Surgery, Korea University College of Medicine, Seoul, 2Division of HBP Surgery & Liver Transplantation, Department of Surgery, St. Vincent’s Hospital, Suwon, 3Department of Surgery, Inje University Paik Hospital, Ilsan, Korea 
Received November 15, 2018; Revised February 28, 2019; Accepted March 29, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
 Abstract
Backgrounds/Aims: Essential nutritional support and nutrition therapy for patients with hepatobiliary and pancreatic diseases undergoing surgery is critical, as it may improve clinical outcome. How to implement rational fluid therapy and nutritional support after surgery and effectively protect organ function is crucial for postoperative recovery. The aim this study was to examine the safety and efficacy of peripheral nutrition fluid (MG-TNA®) in patients undergoing surgery for hepatobiliary and pancreatic disease.
Methods: All adult patients undergoing surgery for hepatobiliary and pancreatic disease received peripheral nutrition fluid (MG-TNA®) on the second postoperative day for 3 days. During administration of parenteral nutrition, patients were closely monitored for adverse effects (primary endpoint). Secondary endpoints included nutritional parameters such as serum prealbumin, transferrin, and creatine kinase (CK) levels.
Results: Thirty patients completed the study and were included in the full analysis set. There was no evidence of metabolic complications such as hyperglycemia, azotemia, hypertriglyceridemia, metabolic acidosis and hypokalemia. In addition, there were no adverse effects. There was a significant decrease in serum prealbumin and CK on the third postoperative day (p<0.0001). Although not statistically significant, serum transferrin levels tended to decrease (p=0.0519).
Conclusions: Administration of peripheral nutrition fluid (MG-TNA®) during postoperative period in patients undergoing surgery for hepatobiliary and pancreatic disease proved to be safe with improvement of the nutritional state of the patient.
Keywords : Nutritional support; Fluid therapy; Safety; Efficacy